Key Highlights
- Mirum Pharmaceuticals (NASDAQ:MIRM) reported a net loss of USD 898.1 million for the nine months ended September 30, 2026, against a loss of USD 17.6 million a year earlier.
- The third quarter net loss was USD 40.8 million, compared with Net Income of USD 2.9 million in the third quarter of 2025.
- Unrestricted cash, cash equivalents and investments totaled USD 500.5 million, up from USD 391.4 million at December 31, 2025.
- The FDA approved zilurgisertib, sold as Atebrioz, in September 2026 for fibrodysplasia ossificans progressiva in patients aged 12 and over.
A Very Large Nine-Month Loss
Mirum Pharmaceuticals (NASDAQ:MIRM) filed its Quarterly Report on November 3, 2026, for the period ended September 30. The nine-month net loss was USD 898.1 million, and the accumulated Deficit grew to USD 1.6 billion from USD 667.5 million at December 31, 2025, an increase consistent with that loss. The third quarter loss alone was USD 40.8 million, which means most of the nine-month figure arose earlier in 2026. The extract reviewed does not itemize the drivers, but it records the January 2026 Bluejay Therapeutics acquisition, the April 2026 rights agreement with Incyte for zilurgisertib, and a September 2026 in-license of a small molecule.
Pipeline Milestones Behind the Spending
Mirum is a rare disease biopharmaceutical company with four approved medicines: Livmarli, Cholbam, Ctexli and Atebrioz. In October 2026 it announced that the Phase 3 EXPAND study of Livmarli met its primary pruritus endpoint in pediatric patients, with a supplemental application planned for the first half of 2027. Its hepatitis D antibody, brelovitug, acquired with Bluejay, met the primary endpoint in the AZURE-1 Phase 3 study. AZURE-4 results are expected in the fourth quarter of 2026, a possible Biologics license application is targeted for the first half of 2027, and a launch, if approved, is targeted for the fourth quarter of 2027. Volixibat has Breakthrough Therapy designation, a possible NDA is planned for the first half of 2027, and primary biliary cholangitis data are due in the first quarter of 2027.
Cash Runway, Takeda Orders and Competition
Management said it expects continued net losses and may need Equity offerings, debt, collaborations or licensing to fund trials, launches and milestone payments, and it may be unable to raise funds on favorable terms. Product Revenue can swing from quarter to quarter because of large periodic orders from Takeda and distributors and variable consideration estimates. Some products could face competition from compounded or generic entrants where Patent exclusivity has lapsed. The pipeline also includes a Phase 2 BLOOM study of MRM-3379 in Fragile X syndrome with topline data expected in 2027, and a study of zilurgisertib in patients younger than 6 years is ongoing. The extract did not include product sales figures, so revenue growth is not assessed here. No share price move is cited.
Where Things Stand
The loss is large in the filing, but the extract does not explain how much came from acquisitions, licensing or other items, so a precise cause cannot be assigned from the supplied text. What it shows is a company that spent heavily on new Assets in 2026 while its cash rose to USD 500.5 million. For Mirum Pharmaceuticals (NASDAQ:MIRM), the next catalysts are AZURE-4 results in the fourth quarter of 2026, primary biliary cholangitis data in the first quarter of 2027, and regulatory submissions in the first half of 2027.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...